-
Dongyangguang Pharmaceutical, Qilu...59 new drugs were approved for clinical trials, Hengrui’s 11th
Time of Update: 2021-09-13
3 billion imported blockbuster new drugs are reported for production; Two Class 1 new drugs of Zhengda Tianqing and Cinda were approved for clinical use; New anti-AD drug, the first domestic Tau antibody to apply for clinical application; Kelun, Hausen, CSPC.
-
New Drugs | Inventory of domestic production status of original research new drugs in the first
Time of Update: 2021-04-19
In China, the drug's marketing application was accepted by CDE in February 2021, and was subsequently included in the priority review for the indication β-thalassemia.
In China, the drug's marketing application was accepted by CDE and was subsequently included in priority review.
-
[drug gajun] among the approved new drugs in 2017, these 12 drugs have unlimited potential. CDE
Time of Update: 2018-03-26
In 2017, 12 new drugs were approved by FDA with unlimited potential In 2017, 47 new drugs were approved by FDA Recently, clarivate analytics, an American company, analyzed and predicted them It is est
-
Great news! Heavyweight new drugs are on the market, domestic anti-cancer new drugs enter FDA, drug
Time of Update: 2018-02-22
Good news: the US FDA approved the listing of Gilead new drug On February 8, Gilead Sciences announced that the US FDA approved the listing of its new drug biktarvy as a single tablet therapy once a d
-
22 ophthalmology category 1 new drugs are coming to Hengrui, 3 new drugs are expected to be launched
Time of Update: 2022-05-01
Among the new ophthalmic drugs currently under development by the company, KH906 eye drops, a class 1 new drug, has entered Phase I clinical trials for the treatment of corneal neovascularization; KH737 eye drops, which have been approved for clinical use, are used to delay the progression of myopia in children .
-
Wanchun Pharmaceutical’s rejection of new drug listing, will Hengrui be implicated in the development of new drugs, will it be a “point of no return”?
Time of Update: 2022-01-12
Can Hengrui break through the “nine deaths and a lifetime” of new drug research and development?Wanchun Pharmaceutical’s core product Punablin was rejected from listing in the United States, plummeting 60%, and its market value fell to less than US$200 million .
-
Progress in new drugs Deqi Pharma's first new drug was approved for listing in China!
Time of Update: 2022-01-01
S. Food and Drug Administration (FDA) approved selinexor (XPOVIO®) combined with low-dose dexamethasone for the treatment of patients with refractory relapsed multiple myeloma (rrMM) .
In addition, Karyopharm announced that the ongoing phase 3 SIENDO trial of selinexor (XPOVIO®) for the treatment of endometrial cancer patients has completed the planned interim invalidity analysis.
-
Domestic Class 1 new drugs broke out! Cinda, Hausen... the sales of 12 innovative drugs soared, and the 21st Class 1 new drug was born this year
Time of Update: 2021-11-04
Since 2021, the number of Class 1 new drugs approved for marketing for the first time in China has reached 21, focusing on the fields of anti-tumor and anti-infection, and 9 new drugs are expected to participate in a new round of medical insurance negotiations .
-
Domestic Class 1 new drugs broke out! Sales of 12 innovative drugs soared, the 21st category 1 new drug was born this year
Time of Update: 2021-11-04
Since 2021, the number of Class 1 new drugs approved for marketing for the first time in China has reached 21, focusing on the fields of anti-tumor and anti-infection, and 9 new drugs are expected to participate in a new round of medical insurance negotiations .
-
Chia Tai Tianqing, Hausen, Hengrui...78 new drugs were approved for clinical use, Qilu biologics broke out, and influenza 1 new drugs struck
Time of Update: 2021-09-19
10) Approved domestic/imported new drug listing application Disulumab is a "first-in-class" anti-RANKL monoclonal antibody developed by Amgen, with global sales of approximately US$5 billion in 2020 .
-
incredible! Class 1 new drugs sold 10 billion, innovative drug companies "strike" the 100 billion
Time of Update: 2021-08-28
Sales of terminal protein kinase inhibitors in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern With the increasing popularity of tinib drugs, Betta Pharmaceuticals has faced many challenges during the ten years when icotinib was launched on the market, including medical insurance negotiations, a 76.
-
27 new drugs were approved for clinical use, and “first-in-class” new drugs are still mainly introduced
Time of Update: 2021-08-09
Approved this time in China is a randomized, double-blind, controlled, adaptive phase 3 clinical study, which aims to evaluate the effectiveness and safety of 3D229 combined with paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer.
-
Kelun Class 1 new drugs are coming this year, 7 new drugs have been approved for clinical use
Time of Update: 2021-08-07
Kelun has been approved for clinical new drugs since 2021 Source: China Drug Clinical Trial Publicity Library of Meinenet The SKB337 injection, which is undergoing phase I clinical trials for advanced solid tumor indications, is a new generation of bispecific antibodies for tumor immune checkpoints.
-
BMS has two billion-dollar transactions in two days to introduce new drugs and expand AI-assisted new drug R&D cooperation
Time of Update: 2021-07-29
In March 2019, Xinji (later acquired by BMS) reached a three-year cooperation with Exscientia to jointly explore the use of AI discovery and Research and development of tumor and immune drugs .
-
The number of declared Class 1 new drugs is not as good as the Hengrui family's Guangdong, why has fallen behind in the development of new drugs
Time of Update: 2021-07-14
Data source: Xianda Pharmaceutical Sea Database If the approval status is not "on the hero", what is the status of Guangdong's Class 1 new chemical drug application?
This data does not include the input of supporting APIs, preparations and clinical human resources for the five-year research and development of new drugs .
